15.83
1.85 (13.23%)
| Penutupan Terdahulu | 13.98 |
| Buka | 14.17 |
| Jumlah Dagangan | 3,842,092 |
| Purata Dagangan (3B) | 1,058,404 |
| Modal Pasaran | 1,350,275,200 |
| Harga / Jualan (P/S) | 112.24 |
| Harga / Buku (P/B) | 146.93 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 8 May 2025 |
| Margin Operasi (TTM) | -1,135.42% |
| EPS Cair (TTM) | -1.71 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 5.00% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 297.04% |
| Nisbah Semasa (MRQ) | 2.93 |
| Aliran Tunai Operasi (OCF TTM) | -99.23 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -64.38 M |
| Pulangan Atas Aset (ROA TTM) | -37.66% |
| Pulangan Atas Ekuiti (ROE TTM) | -203.98% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menurun |
| Biotechnology (Global) | Bercampur | Menurun | |
| Stok | Liquidia Corporation | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 5.0 |
| Aktiviti Orang Dalam | -2.5 |
| Volatiliti Harga | 2.0 |
| Purata Bergerak Teknikal | -2.5 |
| Osilator Teknikal | 0.5 |
| Purata | 0.50 |
|
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 13.64% |
| % Dimiliki oleh Institusi | 65.04% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 43.00 (Jefferies, 171.64%) | Beli |
| Median | 38.50 (143.21%) | |
| Rendah | 31.00 (Wells Fargo, 95.83%) | Beli |
| Purata | 37.75 (138.47%) | |
| Jumlah | 4 Beli | |
| Harga Purata @ Panggilan | 25.11 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Jefferies | 15 Aug 2025 | 43.00 (171.64%) | Beli | 25.95 |
| Raymond James | 13 Aug 2025 | 41.00 (159.00%) | Beli | 25.20 |
| Wells Fargo | 13 Aug 2025 | 31.00 (95.83%) | Beli | 25.20 |
| Needham | 12 Aug 2025 | 36.00 (127.42%) | Beli | 24.10 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 11 Sep 2025 | Pengumuman | Liquidia Announces Poster Presentations at the Pulmonary Hypertension Professional Association (PHPN) Symposium |
| 27 Aug 2025 | Pengumuman | Liquidia Corporation to Present at the 2025 Wells Fargo Healthcare Conference |
| 12 Aug 2025 | Pengumuman | Liquidia Corporation Reports Second Quarter 2025 Financial Results and Provides Corporate Update |
| 05 Aug 2025 | Pengumuman | Liquidia Corporation to Report Second Quarter 2025 Financial Results on August 12, 2025 |
| 23 Jun 2025 | Pengumuman | Liquidia Receives $50 Million from Healthcare Royalty (HCRx) Following First Commercial Sale of YUTREPIA™ |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |